Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
$0.355
Movement
0.025 (-6.58%)
as at 9 Oct 2:39pm (20 mins delayed)
52 Week Range
$0.345 - $0.92
1 Year Return
-49.29%
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$4.52 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.90 million
Earnings per share
-0.316
Dividend per share
N/A
Year To Date Return
-38.71%
Earnings Yield
N/A
Franking
-
Share Price
$0.355
Day Change
0.025 (-6.58%)
52 Week Range
$0.345 - $0.92
Yesterday's Close
$0.38
Today's Open
$0.38
Days Range
$0.355 - $0.38
Volume
26,844
Avg. Volume (1 month)
5,654
Turnover
$10,189
as at 9 Oct 2:39pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
Healthcare Shares
Guess which obscure ASX healthcare share just exploded 220% on HUGE news
Cannabis Shares
Off and racing: Zelira shares fly 37% higher on Thursday
Share Gainers
Why has this ASX medicinal cannabis share soared 49% in two days?
Share Market News
Zelira shares rocket 28% before being placed on ice. Here's the latest.
Cannabis Shares
Blazing it? How the top ASX cannabis shares performed in FY21
Cannabis Shares
Why the Zelira (ASX:ZLD) share price is storming 7% higher
Cannabis Shares
Zelira (ASX:ZLD) share price falls despite strong trading update
Share Market News
What will Elite Cannabinoids mean for ASX cannabis shares?
Cannabis Shares
CBD to be sold in pharmacies, ASX cannabis shares react
Share Market News
The sector that'll grow 480% this year, expert says
Best Shares
5 top ASX cannabis shares in 2020
Share Market News
Here's why the Zelira (ASX:ZLD) share price just rocketed to a new high
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 08 Oct 2025 | $0.38 | $0.00 | 0.00% | 2,169 | $0.38 | $0.38 | $0.38 |
| 07 Oct 2025 | $0.38 | $0.00 | 0.00% | 2,499 | $0.38 | $0.38 | $0.38 |
| 06 Oct 2025 | $0.38 | $0.00 | 0.00% | 681 | $0.38 | $0.38 | $0.38 |
| 03 Oct 2025 | $0.38 | $-0.02 | -5.00% | 535 | $0.40 | $0.40 | $0.38 |
| 02 Oct 2025 | $0.40 | $0.00 | 0.00% | 4,425 | $0.41 | $0.41 | $0.40 |
| 01 Oct 2025 | $0.40 | $0.05 | 14.29% | 5,451 | $0.38 | $0.45 | $0.38 |
| 30 Sep 2025 | $0.35 | $0.00 | 0.00% | 12,487 | $0.36 | $0.36 | $0.35 |
| 29 Sep 2025 | $0.35 | $-0.02 | -5.41% | 5,100 | $0.37 | $0.37 | $0.35 |
| 26 Sep 2025 | $0.37 | $-0.03 | -7.59% | 46,479 | $0.40 | $0.40 | $0.36 |
| 25 Sep 2025 | $0.40 | $-0.02 | -4.76% | 65 | $0.42 | $0.42 | $0.40 |
| 24 Sep 2025 | $0.42 | $0.00 | 0.00% | 400 | $0.42 | $0.42 | $0.42 |
| 23 Sep 2025 | $0.42 | $0.00 | 0.00% | 382 | $0.42 | $0.42 | $0.42 |
| 22 Sep 2025 | $0.42 | $0.00 | 0.00% | 867 | $0.42 | $0.42 | $0.42 |
| 19 Sep 2025 | $0.42 | $-0.05 | -10.64% | 25,101 | $0.47 | $0.47 | $0.42 |
| 18 Sep 2025 | $0.47 | $0.09 | 23.68% | 5,174 | $0.38 | $0.47 | $0.38 |
| 17 Sep 2025 | $0.38 | $0.00 | 0.00% | 67 | $0.38 | $0.38 | $0.38 |
| 15 Sep 2025 | $0.38 | $-0.03 | -7.32% | 4,480 | $0.40 | $0.42 | $0.38 |
| 12 Sep 2025 | $0.41 | $0.03 | 8.00% | 3,122 | $0.38 | $0.43 | $0.38 |
| 11 Sep 2025 | $0.38 | $0.00 | 0.00% | 2,479 | $0.38 | $0.38 | $0.38 |
| 10 Sep 2025 | $0.38 | $0.00 | 0.00% | 14 | $0.38 | $0.38 | $0.38 |
| 09 Sep 2025 | $0.38 | $0.00 | 0.00% | 2,413 | $0.38 | $0.38 | $0.38 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 17 Jan 2025 | Oludare Odumosu | Expiry | 110,334 | $69,510 |
As advised by the company. Lapsed because conditions have not been met.
As per announcement on 20/01/2025 |
| 17 Jan 2025 | Osagie Imasogie | Expiry | 335,094 | $211,109 |
As advised by the company. Lapsed because conditions have not been met.
|
| 13 Dec 2024 | Osagie Imasogie | Issued | 3,500,000 | $1,400,000 |
As advised by the company. USD,3,500,000 Convertible Notes, Issue
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. He has over 15 years' experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Mr Osagie Imasogie has over 30 years of experience in law, finance, business management, healthcare, and the pharmaceutical industry. He is co-founder and Senior Managing Partner of PIPV Capital, a Private Equity firm focused on the Life Sciences sector. Prior to co-founding PIPV Capital, he conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. He has held senior legal, commercial, and R&D positions at pharmaceutical companies including GSK, SmithKline, DuPont Merck, and Endo, where he was founding General Counsel and Senior Vice President for Corporate Development.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Dr Odumosu was Ilera Healthcare's first Chief Operating Officer, leading the design, implementation, and management of Ilera's business operations following its license award in 2017. He oversaw day-to-day operations of Ilera's vertically integrated grower/processor, wholesale, and dispensary and led the formulation of Ilera's proprietary cannabinoid-based product.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialisation of several products across various therapeutic categories. He has nearly 20 years of experience in healthcare, building a foundation of knowledge across marketing and the commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell has led a diverse career in healthcare, life sciences, and public service focused in the Greater Philadelphia area. She was formerly a principal with O'Donnell Associates, working with clients including non-profit organisations, universities, and life science companies such as Cephalon Pharmaceuticals.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 9.54% |
| Sunset Capital Management Pty Ltd | 573,725 | 4.82% |
| Securities Vault Pty Ltd | 488,059 | 4.10% |
| Quincy Street Capital Llc | 456,622 | 3.84% |
| Sharri J Rochlin | 393,168 | 3.30% |
| Osagie Imasogie | 393,168 | 3.30% |
| Mr Zoltan Kerekes | 393,168 | 3.30% |
| Ms Lisa Gray | 381,988 | 3.21% |
| Bnp Paribas Nominees Pty Ltd | 341,932 | 2.87% |
| Mera I Llc\C | 332,479 | 2.79% |
| Mr Torsten M Geers | 307,454 | 2.58% |
| Mr Steve Shapiro | 302,571 | 2.54% |
| Mara Gordon | 252,242 | 2.12% |
| Mr Saul Shorr Mrs Margaret Shorr | 151,285 | 1.27% |
| Dr Chanda Latrice Macias | 146,479 | 1.23% |
| Mera Ii Llc\C (i) | 133,372 | 1.12% |
| Oludare Odumosu | 131,766 | 1.11% |
| Citicorp Nominees Pty Limited | 121,342 | 1.02% |
| Mr Daniel Hexter Mrs Shannon Hexter | 103,389 | 0.87% |
| Geers Egag Llc | 85,715 | 0.72% |